At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Biopsy Procedure, Biospecimen Collection, and 3 other interventions for Advanced Malignant Solid Neoplasm and 6 related conditions. Active but no longer recruiting, targeting 89 participants across 51 sites.
Signals
Detailed Summary
This phase II trial studies how well olaparib works in treating patients with glioma, cholangiocarcinoma, or solid tumors with IDH1 or IDH2 mutations that has spread from where it first started (primary site) to other places in the body (metastatic) and that does not respond to treatment (refractory). Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Timeline
Arms & Interventions
Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression, unacceptable toxicity, withdrawal of consent or death. Patients undergo a CT scan and/or MRI, as well as a tumor biopsy and blood sample collection on study.
Interventions
Undergo tissue biopsy
Undergo blood sample collection
Undergo a CT scan
Undergo a MRI
Given PO